Second-line therapy for severe active rheumatoid arthritis (in patients with normal kidney function)
FDA's Arthritis Advisory Committee recommend- ed approval (2/4)
QLT PhotoTherapeutics Inc. (Canada)
Photofrin
Photosensitive drug (produces toxic oxygen compound when light activated)
To reduce obstruction and for palliation of symptoms in patients with non-small cell lung cancer (NSCLC)
FDA's Oncologic Drugs Advisory Committee voted 10-1 to approve for shrinking tumors in patients with inoperable early-stage NSCLC, but voted 9-2 against approval for palliation of symptoms in advanced NSCLC (9/18)